Vernalis CEO Ian Garland said the company plans to acquire firms and sign in-licensing deals to broaden its drug portfolio. The U.K. biotech firm plans to buy companies working on late-stage drugs focused on oncology and the central nervous system, as well as in-license treatments that are in early-stage development, Garland said.

Full Story:

Related Summaries